TIPS-22 A TWO-PART, PHASE 1 STUDY OF RHENIUM (186RE) OBISBEMEDA (186RNL) DELIVERED BY CONVECTION ENHANCED DELIVERY (CED) FOR RECURRENT, REFRACTORY, OR PROGRESSIVE CHILDHOOD EPENDYMOMA AND HIGH-GRADE GLIOMA (HGG)

ABSTRACT: Abstract INTRODUCTION: Childhood ependymoma and HGG are difficult tumors to treat. Recurrent ependymoma is treated with re-resection and multiple rounds of EBRT. HGG is treated with chemoradiation followed by clinical trials, if available. While EBRT remains a central component of management, it is limited by tolerance of the surrounding normal brain tissue. 186RNL permits the selective delivery of beta-emitting radiation with excellent tumor retention. In an adult Phase 1/2 trial for recurrent glioblastoma (NCT01906385), the mean absorbed dose to the tumor was ~300-500 Gy, markedly higher than absorbed doses typically delivered by EBRT. Despite this, no dose-limiting toxicity was observed, and no treatment-related serious adverse events have occurred. Here, we describe the first pediatric

SUBMITTER:  

PROVIDER: S-EPMC10402359 | biostudies-literature | 2023 Aug

REPOSITORIES: biostudies-literature